Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion type Assertion NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_head.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion description "[Leptin antagonists have been developed for clinical use and leptin and its associated pathways may also provide much needed novel therapeutic targets for gastro-oesophageal adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_provenance.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion evidence source_evidence_literature NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_provenance.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion SIO_000772 24569475 NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_provenance.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion wasDerivedFrom befree-20150227 NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_provenance.
- NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_assertion wasGeneratedBy ECO_0000203 NP534365.RA2wUPD4zysqTORAS29UI7nZ_8l8uhaCsCcBwGkpfZ-rU130_provenance.